Clinical trials: Vascular And Immunologic Diseases
Multiple Myeloma
Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma
This is a research study for patients with newly diagnosed multiple myeloma. Multiple myeloma remains a non-curable disease however, newer medications and their combinations appear to provide higher response rates and higher…
- Trial name
- NCT00116961
- Testing
- Velcade, Doxil, Dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan Rogel Cancer Center
Multiple Myeloma
Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM)
This is randomized, multicentre study aimed to compare a standard maintenance therapy with Interferon-Dexamethasone with an experimental therapy based on Thalidomide-Dexamethasone in patients with multiple myeloma who responded…
- Trial name
- NCT00633542
- Testing
- thalidomide, interferon alpha
- Where
- Italy
- Volunteers
- 103 people
- Sponsor
- Università Politecnica delle Marche
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease
Phase II trial to study the effectiveness of interleukin-12 in treating patients with previously treated non-Hodgkin's lymphoma or Hodgkin's disease.
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma
- Trial name
- NCT00003210
- Testing
- recombinant interleukin-12, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Atrial Fibrillation
Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors
Acalabrutinib and Zanabrutinib are highly effective drugs used to treat Chronic Lymphocytic Leukemia, but they are associated with high blood pressure and abnormal heart rhythms.
- Conditions
- Chronic Lymphocytic Leukemia, Atrial Fibrillation, Hypertension, Cardiotoxicity
- Trial name
- SENTINEL (NCT06211413)
- Testing
- no intervention
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Multiple Myeloma
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
To learn if isatuximab can help to control highrisk MM when given in combination with lenalidomide after an autologous stem cell transplantation (ASCT).
- Trial name
- NCT05776979
- Testing
- Isatuximab, lenalidomide
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
The primary objective of this observational study is to document and describe current treatment regimens and disease progression of patients with Multiple Myeloma (MMY).
- Trial name
- NCT01241396
- Testing
- Any MMY treatment
- Where
- 159 sites in Algeria, Austria and 19 more
- Volunteers
- 2,396 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Chronic Spontaneous Urticaria
A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous lirentelimab (AK002) in adult subjects with H-1 antihistamine refractory chronic spontaneous…
- Trial name
- MAVERICK (NCT05528861)
- Testing
- Lirentelimab (AK002)
- Where
- 67 sites in United States, Germany and 1 more
- Volunteers
- 127 people
- Sponsor
- Allakos Inc.
Diabetes, Diabetic Foot
Diabetic Foot Ulcer Study Comparing Cytal Wound Matrix 1-Layer to Standard of Care
This is a two-armed randomized controlled trial (RCT) primarily aimed at determining if application of Cytal Wound Matrix 1-Layer intervention to diabetic foot ulcers shows improved wound closure rates when compared to standard…
- Conditions
- Diabetes, Diabetic Foot, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
- Trial name
- NCT03626623
- Testing
- Cytal Wound Matrix 1-Layer, Standard of Care (SOC)
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Integra LifeSciences Corporation
Multiple Myeloma
Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone
Recent prospective multicenter phase II study assessed the efficacy and tolerability of lower dose lenalidomide (15mg) and dexamethasone (20mg) in frail patients with relapsed or refractory MM.
- Trial name
- LENDER (NCT03809780)
- Testing
- Lenalidomide, Dexamethasone
- Where
- South Korea
- Volunteers
- 70 people
- Sponsor
- Kosin University Gospel Hospital
Multiple Myeloma
Cardiovascular Complications of Carfilzomib Treatment
Accumulating evidence supports the hypothesis of a pathophysiological role of the Ubiquitin Proteasome System (UPS) in the process of atherosclerosis and vascular function.
- Trial name
- NCT03543579
- Where
- Greece
- Volunteers
- 46 people
- Sponsor
- University of Athens
Multiple Myeloma
Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line
The purpose of this study is to quantify the burden of treatment in relapsed or refractory multiple myeloma in patients receiving lenalidomide after one prior treatment for myeloma.
- Trial name
- NCT01430546
- Where
- Sweden
- Volunteers
- 133 people
- Sponsor
- Hareth Nahi
Multiple Myeloma
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.
- Trial name
- MajesTEC-2 (NCT04722146)
- Testing
- Teclistamab, Daratumumab, Pomalidomide
- Where
- 27 sites in United States, Australia and 3 more
- Volunteers
- 140 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Spontaneous Urticaria
OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients
This trial assessed the efficacy of optimized re-treatment therapy with omalizumab (150mg or 300mg) after relapse, in participants with Chronic Spontaneous Urticaria who were clinically well-controlled following their first…
- Trial name
- OPTIMA (NCT02161562)
- Testing
- omalizumab
- Where
- 35 sites in Argentina, Brazil and 6 more
- Volunteers
- 314 people
- Sponsor
- Novartis Pharmaceuticals
Hematological Malignancies, Leukemia
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies
This research study uses a drug called cyclophosphamide to decrease the incidence of GVHD in matched sibling hematopoietic stem cell transplant. In doing so, the goal of the study is to increase overall survival.
- Conditions
- Hematological Malignancies, Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT01315132
- Testing
- Matched Sibling Allogeneic Transplantation
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma
FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Drugs used in chemotherapy such as FR901228 use different ways to stop cancer cells from dividing so they stop growing or die. Phase II trial to study the effectiveness of FR901228 in treating patients who have relapsed or…
- Conditions
- DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT00066638
- Testing
- Romidepsin, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Peripheral Neuropathy, Toxicity Due to Chemotherapy
Acupuncture for Chemotherapy-induced Peripheral Neuropathy
The purpose of this study is to evaluate whether acupuncture can be effective for chemotherapy-induced peripheral neuropathy in lymphoma or multiple myeloma patients.
- Conditions
- Peripheral Neuropathy, Toxicity Due to Chemotherapy, Lymphoma, Multiple Myeloma
- Trial name
- NCT01892852
- Testing
- Acupuncture
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- Pusan National University Hospital
Multiple Myeloma
Thalidomide to Patients With Previously Untreated Multiple Myeloma
The purpose of this study is to test the effect of thalidomide in patients with multiple myeloma. The patients receive either thalidomide or a placebo tablet (neither patient nor doctor know which of these are given) in addition…
- Trial name
- NCT00218855
- Testing
- thalidomide
- Where
- Norway
- Volunteers
- 363 people
- Sponsor
- Norwegian University of Science and Technology
Refractory Multiple Myeloma, Stage II Multiple Myeloma
Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma
This phase I trial is studying the side effects and best dose of temsirolimus when given together with lenalidomide in treating patients with previously treated multiple myeloma.
- Conditions
- Refractory Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00398515
- Testing
- lenalidomide, temsirolimus, pharmacological study
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)
Cyclophosphamide is a chemotherapy agent with known activity in myeloma. The new regimen that we will test in this study is called CVDD and contains Cyclophosphamide with Bortezomib (VELCADE), Pegylated Liposomal Doxorubicin…
- Trial name
- NCT00750815
- Testing
- Cyclophosphamide, Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Myeloma
Myeloma Registry Platform (MYRIAM)
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics…
- Trial name
- MYRIAM (NCT03308474)
- Testing
- Routine care as per site standard.
- Where
- Germany
- Volunteers
- 2,200 people
- Sponsor
- iOMEDICO AG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.